Related Experiment Video
Updated: Mar 21, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors
Manuela Terranova-Barberio1, Scott Thomas1, Pamela N Munster1
1Department of Medicine, Division of Hematology & Oncology, University of California, Room A722, 1600 Divisadero St, Box 1770, San Francisco, CA 94115, USA.
Abstract:
Immune surveillance should be directed to suppress tumor development and progression, involving a balance of coinhibitory and costimulatory signals that amplify immune response without overwhelming the host. Immunotherapy confers durable clinical benefit in 'immunogenic tumors', whereas in other tumors the responses are modest. Thus, immune checkpoint inhibitors may need to be combined with strategies to boost immune response or increase the tumor immune profile. Epigenetic aberrations contribute significantly to carcinogenesis. Recent findings suggest that epigenetic drugs prime the immune response by increasing expression of tumor-associated antigens and immune-related genes, as well as modulating chemokines and cytokines involved in immune system activation. This review describes our current understanding regarding epigenetic and immunotherapy combination, focusing on immune response priming to checkpoint blockade.
Related Concept Videos
Tumor Immunotherapy
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Mitogens and the Cell Cycle
Pharmacogenomics: Identification of New Drug Targets

